Detalhe da pesquisa
1.
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
J Pharmacol Exp Ther
; 352(3): 568-78, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576073
2.
Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD.
J Med Chem
; 66(16): 11476-11497, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561958
3.
A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases.
Sci Transl Med
; 14(638): eabl6328, 2022 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35353541
4.
Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease.
J Med Chem
; 64(13): 9100-9119, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34142835
5.
Transient receptor potential ankyrin 1 channel localized to non-neuronal airway cells promotes non-neurogenic inflammation.
PLoS One
; 7(8): e42454, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22905134